[Clinical efficacy of TS-1 in refractory bone recurrence of a postoperative squamous lung cancer patient].
We need more effective treatments for refractory non-small cell lung cancer. A 61-year-old man had a recurrence in the left ninth rib invading the chestwall 4 years after resection of squamous cell lung cancer. The metastatic lesion grew larger even after 3 different regimens of systemic chemotherapy and local irradiation. Then he started to receive 120 mg of TS-1 daily for 28 days followed by 14 days of rest (1 course). A partial response was achieved after 2 courses of the treatment and continued for 6 weeks. Doses of oxycodone hydrochloride could be reduced to one-sixth of the initial dose according to tumor regression. This is the first report to show the effectiveness of TS-1 for a refractory recurrence of lung cancer to the bone.